Castle Biosciences gains on positive data for Barrett's Esophagus Test results

Castle Biosciences

25/10/2022 19:11

** Castle Biosciences Inc  CSTL.O  shares up 8.2% at $22.02
    ** New data shows use of CSTL's TissueCypher Barrett's
Esophagus Test results can significantly improve management
decisions for Barrett’s esophagus patients with low-grade
dysplasia
    ** TissueCypher Barrett’s Esophagus test is designed to
predict development of high-grade dysplasia and/or esophageal
cancer in patients with Barrett’s esophagus
    ** Accounting for session gains, company's shares down 49%
YTD
 (Reporting by Arshreet Singh in Bengaluru)